Tech Company Financing Transactions

True North Therapeutics Funding Round

True North Therapeutics closed a $40 million Series C funding round on 12/3/2015. Investors included New Leaf Venture Partners, Baxalta Ventures and Cowen Capital Partners.

Transaction Overview

Company Name
True North Therapeutics
Announced On
12/3/2015
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series C
Investors

New Leaf Venture Partners (Lead Investor) (Isaac Manke)

Baxalta Ventures (Geeta Vemuri)

Cowen Capital Partners

Kleiner Perkins Caufield & Byers (Beth Seidenberg)

MPM Capital (James Scopa)

OrbiMed (Carl Gordon)

Perceptive Advisors

SR One Capital Management (Rajeev Dadoo)

Proceeds Purpose
Proceeds from the financing will be used to advance the clinical development of its lead complement inhibitor, TNT009, for Cold Agglutinin Disease (CAD), as well as other rare diseases targeting the Complement system.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
951 Gateway Blvd.
South San Francisco, CA 94080
USA
Phone
(650) 872-4700
Website
www.truenorthrx.com
Email Address
[email protected]
Overview
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company's lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis.
Profile
True North Therapeutics LinkedIn Company Profile
Social Media
True North Therapeutics Company Twitter Account
Company News
True North Therapeutics News
Facebook
True North Therapeutics on Facebook
YouTube
True North Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Nancy Stagliano
  Nancy Stagliano LinkedIn Profile  Nancy Stagliano Twitter Account  Nancy Stagliano News  Nancy Stagliano on Facebook
Chief Financial Officer
Pamela Wapnick
  Pamela Wapnick LinkedIn Profile  Pamela Wapnick Twitter Account  Pamela Wapnick News  Pamela Wapnick on Facebook
Chief Medical Officer
Gary Patou
  Gary Patou LinkedIn Profile  Gary Patou Twitter Account  Gary Patou News  Gary Patou on Facebook
VP - Bus. Development
Adam Rosenthal
  Adam Rosenthal LinkedIn Profile  Adam Rosenthal Twitter Account  Adam Rosenthal News  Adam Rosenthal on Facebook
VP - R & D
Graham Parry
  Graham Parry LinkedIn Profile  Graham Parry Twitter Account  Graham Parry News  Graham Parry on Facebook

 

 

Browse more venture capital transactions:

Prev: 12/3/2015: Riptide IO venture capital transaction
Next: 12/3/2015: Figma venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

Our team works diligently to record every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.